Obesity is an important causative factor in morbidity, disability and premature death. Increasing levels of obesity will impose enormous health, financial and social burdens on worldwide society unless effective interventions are implemented. For many obese individuals, diet and behavioural modification need to be supplemented by pharmacotherapy. Preclinical research has revealed a greater understanding of the complex nature of the hypothalamic regulation of food intake and has generated a wide range of new molecular targets for the development of drug candidates for obesity treatment. As shown by the clinical results that have been obtained with this next generation of therapies, some approaches, for example, fixed-dose drug combinations, have already demonstrated an ability to deliver levels of efficacy that are not achievable with the current antiobesity drug therapies. The regulatory and marketing landscape for development, registration and commercialisation of novel centrally acting drugs for treatment of obesity and related metabolic disorders has changed substantially in recent years. Now a much greater emphasis is placed on tolerability and safety, as well as efficacy. In this review we briefly describe the therapeutic approaches to tackle obesity that are in late-stage clinical development. We then discuss drugs in late-stage development for the treatment of obesity and also future directions.
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Obesity is a predisposing factor for life-threatening disorders, such as dyslipidaemia, hypertension, proinflammatory, atherogenesis, pre-diabetes (i.e., insulin resistance and impaired glucose tolerance) and type 2 diabetes, 2 --4 all of which are risk factors for increased cardiovascular ill health and mortality. 5 --7 Recent government figures have revealed that prevalence of type 2 diabetes in the United Kingdom has doubled in the past 15 years. 8 Obesity is also a causative factor in p30% cases of cancer of the colon, breast, kidney and digestive tract, 9 sleep apnoea, aggravated arthritis, gout and gallstones. 10 --13 Moreover, obesity is associated with psychological problems, including depression and low self-esteem.
Although an approximate doubling of risk for obesity-associated diseases does not occur until body mass index (BMI) exceeds 40 kg m --2 (morbid obesity), when the global prevalence of obesity is added into the equation, the medical consequences of this epidemic could overwhelm the health-care systems in many countries. Although for Caucasians the risk of developing comorbid diseases like type 2 diabetes increases substantially at a BMI of X30 kg m --2 , for many non-Caucasian races, including Asians and Hispanics who tend to develop the more dangerous abdominal form of obesity, their chances of developing these lifethreatening metabolic diseases occur at much lower BMI values. 14 --17 Increasing obesity levels will impose enormous health, financial and social burdens on worldwide society unless effective interventions are implemented. For many obese individuals, diet and behavioural modification need to be supplemented by pharmacotherapy, or increasingly, bariatric surgery, because attempted adherence to a balanced diet and healthy lifestyle has not addressed this problem.
In this review, we briefly describe the current situation for therapeutic approaches to tackle the problem of obesity. We then discuss compounds in late-stage clinical development for the treatment of obesity and also future directions.
THE STRATEGIC LANDSCAPE FOR DEVELOPING AND MARKETING CENTRALLY ACTING ANTIOBESITY DRUGS
A brief overview of antiobesity drugs Clinical guidance on the use of antiobesity drugs states that they should be an adjunct to first-line treatment, that is, exercise and lifestyle modification. Following the recent withdrawal of sibutramine, there are currently no centrally acting drugs approved for the treatment of obesity in Europe. In the United States, the only central nervous system (CNS) drugs used to treat obesity are the psychostimulant, sympathomimetics that were approved many years ago as short-term anorectic treatments (p12 weeks). They include phentermine, d-amphetamine, methamphetamine, benzphetamine, phendimetrazine and diethylpropion. Orlistat (Xenical), which is an inhibitor of gastric and pancreatic lipases that blocks fat absorption from the gut, 18 is the only approved peripherally acting antiobesity drug. Reduced dose strength orlistat (Alli) is the first prescription antiobesity drug that has received approval in Europe and the United States to be sold 'over the counter'. A list of approved antiobesity drugs and late-stage drug candidates is provided in Table 1 .
Two recent events have substantially changed the regulatory and marketing landscape for the development, registration and commercialisation of novel centrally acting drugs for the treatment of obesity and related metabolic disorders.
The first relates to the development and demise of the cannabinoid CB 1 (cannabinoid receptor type 1) receptor antagonist, rimonabant. In clinical trials, rimonabant was efficacious in treating obesity with or without associated comorbidities. 19 --22 Furthermore, it produced improvements in type 2 diabetes (glycated haemoglobin (HbA 1C )) and dyslipidaemia (triglycerides and high-density lipoprotein cholesterol) statistically greater than those due to weight loss alone. 19 --22 Rimonabant was approved for use in all 25 European Union countries by the European Medicines Agency (EMA) in June 2006. However, in the United States, concerns were expressed about the safety of rimonabant, and especially over the increased incidence of anxiety, depression and suicidal ideation. 22, 23 After an overwhelming vote for nonapproval was sent to the US Food and Drug Administration (FDA) by the independent Neuroendocrinology Pharmaceutical Advisory Committee, Sanofi-Aventis (Paris, France) withdrew the licensing application of rimonabant in the United States. An increasing number of reports of psychiatric adverse events and suicidality among patients taking rimonabant prompted EMA to suspend its marketing authorisation in Europe in October 2008.
The other event that has significantly influenced the landscape for the development of antiobesity drugs is the withdrawal of sibutramine in Europe and the United States. The results from the Sibutramine Cardiovascular OUTcome (SCOUT) study 24 rapidly led to the suspension by EMA of the drug's marketing authorisation for all European Union countries. After a review of these safety data by the Neuroendocrinology Advisory Committee of FDA in 2010, Abbott Pharmaceuticals (Abbott Park, IL, USA) agreed to its request voluntarily to withdraw sibutramine from the US market. SCOUT was an outcome trial conducted in a group of patients at high cardiovascular risk and the primary cardiovascular endpoints were the occurrence of nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest or cardiovascular death. 24 The frequency of the nonfatal, primary event was 11.4% higher in subjects on sibutramine treatment compared with placebo. 24 Viewed in isolation, this finding would provide a substantial case for the suspension or withdrawal of sibutramine. However, the issue is far less clearcut as this outcome trial was performed in a subject population that was expressly excluded from treatment with sibutramine in the European Summary of Product Characteristics (SPC) and the US Product Label. 25 The issue is further clouded because in the SCOUT trial there was no increase in frequency of cardiovascular events in the cohort of subjects with type 2 diabetes, who were eligible for treatment with sibutramine according to its labelling. 24 The latter outcome was consistent with other evidence on cardiovascular risk provided by Abbott. The insistence of EMA to request what was an 'off-label' clinical trial in an inappropriate patient population merely to obtain a definitive outcome raises a number of difficult questions. First, was it ethical to risk the safety of high cardiovascular risk, obese patients by including them in a trial of sibutramine; a drug that was not appropriate for the management of their obesity? Second, was it reasonable and fair to determine the safety of sibutramine based on results obtained in patients who should have not be prescribed the drug? Furthermore, the inclusion of so many patients in the SCOUT trial, who should not have been on sibutramine treatment, probably biased the data set to an extent that no meaningful assessment could be made about its long-term impact on cardiovascular outcomes in the appropriate patient population. Overall, the affair has done no credit to EMA. It could also have created a potentially false safety scare over the appropriate medical use of sibutramine. Finally, it has almost certainly reinforced the opinion of the pharmaceutical industry that the regulatory agencies apply disproportionately onerous conditions on the development and registration of new antiobesity drugs.
Unfortunately, rimonabant and sibutramine are the latest in a long line of centrally acting anti-obesity drugs that have been linked with major safety concerns. In the 1950s, d-amphetamine and methamphetamine were widely prescribed as appetite suppressants, but their frequent diversion and abuse led them to become highly restricted controlled drugs. In the 1990s, fenfluramine and d-fenfluramine were withdrawn after their use was linked with life-threatening cardiovascular adverse events, that is, primary pulmonary hypertension 26, 27 and cardiac valvulopathy. 28, 29 The outcome has been to make health-care providers wary about centrally acting antiobesity drugs, and to make safety the priority in the development of novel drugs. In this climate, it is not surprising that many senior executives within the pharmaceutical industry remain pessimistic about the chances of successfully registering new antiobesity drugs, especially ones that have a CNS mechanism of action. The regulatory environment for the development and approval of new antiobesity drugs The three candidates in Table 1 at the pre-registration phase, that is, Contrave, Qnexa and lorcaserin (Lorqess), are all centrally acting agents developed by small biotech companies, that is, Orexigen (La Jolla, CA, USA), Vivus (San Diego, CA, USA) and Arena Pharmaceuticals (San Diego, CA, USA), respectively. Two biotechs have now struck licensing deals with major pharmaceutical companies, indicating that the big players have been content to let most of the development risks reside within the biotech sector. The new drug applications (NDAs) for these compounds were all reviewed in 2010 by the FDA and its independent Neuroendocrinology Pharmaceutical Advisory Committee. Although the Advisory Committee voted to recommend the approval of Contrave in December 2010, the FDA declined the application in January 2011 on cardiovascular safety grounds. The FDA insisted that it could not approve Contrave without evidence from a long-term cardiovascular outcome trial to show that Contrave does not increase the risk of heart attack and stroke. The increased cardiovascular adverse events responsible for withdrawal of sibutramine would have raised the level of concern, especially as Contrave and sibutramine are known to increase blood pressure. Orexigen recently reached agreement with the FDA over the design of the cardiovascular outcome trial and will conduct it with a view to resubmitting the NDA in 2013 or 2014. In spite of the impressive efficacy of Qnexa as an antiobesity treatment, the FDA Advisory Committee voted not to recommend its approval on safety grounds at the hearing in July 2010; the most important area of concern was a possible link between topiramate and birth defects in children. To answer this question, Vivus is conducting a retrospective review of the incidence of birth defects in woman taking topiramate during pregnancy. In the meantime, the company submitted a revised NDA in October 2011 for the use of Qnexa in the treatment of obesity in men and women without child-bearing potential. 30 The ultimate objective would be to extend the labelling of Qnexa to include all women if the results from its retrospective analysis are supportive. Vivus also recently announced that it had submitted a dossier to EMA for the European registration of Qnexa.
31 On 22 February 2012 the FDA's Advisory Committee voted 20--2 to recommend the approval of Qnexa for use in the treatment of adult obesity in males and females. Following a vote against the approval of lorcaserin by the FDA's independent Advisory Committee in September 2010, the FDA issued a non-approvable letter 1 month later stating that its major safety concern was an increased incidence of unexplained tumours in rats in the long-term carcinogenicity studies. In January 2012, Arena announced that it had submitted its responses on safety issues to the FDA and had resubmitted the NDA of lorcaserin for consideration by the agency. 32 In spite of these setbacks, there are encouraging signs that Qnexa and lorcaserin will have the chance to gain US approval in the not-too-distant future. A positive outcome for at least one of these drug candidates is essential to help dispel the widely held impression that it is impossible to obtain a marketing authorisation for a new CNS drug in the obesity indication.
Another challenge for development of novel antiobesity drugs is the different clinical efficacy criteria employed by FDA and EMA. The FDA allows the use of two alternative efficacy criteria. First, the difference in mean weight loss between drug candidate and placebo at 1 year should be X5% and this difference must be statistically significant. Second, the proportion of subjects who lose X5% from baseline of body weight in the drug-candidate group should be X35%, and be approximately twice the proportion in the placebo-treated group with the difference again being statistically significant. 33 In contrast, EMA regards the weight reduction from baseline as being more clinically relevant than placebo-subtracted weight loss. Thus, the primary efficacy criterion of EMA for what it considers to be clinically significant weight loss is X10% of baseline body weight at 1 year, which is also X5% greater than achieved on placebo, and this difference should be statistically significant. 34 The EMA guideline also states that where the clinical response is X10% weight loss at the end of 1 year, the proportions of responders in various treatment arms could be considered as an alternative primary efficacy criterion. 34 Although FDA and EMA cite weight reduction as their primary efficacy criterion, these agencies view weight loss per se as a cosmetic outcome. Weight reduction needs to be accompanied by commensurate improvements in cardiovascular risk factors. 33, 34 One critical point is that these criteria are guidelines, not definitive arbitrators of success or failure, and both FDA and EMA retain the absolute right to reach their final decisions about the efficacy and safety of each new drug candidate on a case-by-case basis. A more in-depth analysis of the regulatory hurdles for the development and registration of new antiobesity drugs is provided in our recent review. 35 The commercial landscape for antiobesity drugs Another factor that dampens the pharmaceutical industry's interest in obesity pharmacotherapy is the relatively modest sales of drugs in a therapeutic indication where millions of subjects are eligible for treatment and there is an enormous level of unmet clinical need. In the United States, the reluctance of medical insurers to provide reimbursement for antiobesity drugs is often cited as the main reason why sales of new antiobesity drugs are disappointing. Although it may have a significant contributory influence on sales, the expectations of prescribers and patients are almost certainly a more important factor in the equation. In metaanalyses of trials of antiobesity drugs, Caucasian females aged 35 --55 years are the predominant group, with ethnic minorities and males markedly under-represented. 36, 37 In this population, weight reduction is generally the overriding treatment goal for subjects seeking all types of intervention including bariatric surgery. 38 --40 Moreover, even with bariatric surgery where body weight reductions of 30 --50 kg are achievable, patients' expectations of weight loss often far exceed this level of efficacy. 41 --43 As an example, Kaly et al. 39 reported that subjects enroling for bariatric surgery stated that a 67% reduction of excess body weight would be 'acceptable', whereas a 49% reduction would be 'disappointing'. Similarly, Smiertka and MacPherson 44 described how in a postoperative, follow-up investigation, the value of the health benefits of bariatric surgery, for example, recovery from type 2 diabetes, were largely forgotten in the long term, whereas dissatisfaction with residual obesity remained. With such unrealistic weight loss expectations, it is not surprising that antiobesity drugs that produce 5 --8% reductions from baseline body weight are regarded as ineffective by the majority of patients and physicians. This negative sentiment about the effectiveness of antiobesity drugs is reinforced by the plateau of weight reduction that occurs after 3 --6 months of treatment; an outcome often regarded by patients as an indicator that the drug has lost its pharmacological effect. Consistent with this hypothesis is the finding that even when antiobesity drugs were reimbursed, 70 --80% of subjects remained on therapy for o3 months regardless of whether or not the drugs had been approved for long-term use. 45 Thus, in spite of the increasing prevalence of obesity in the United States, medication use remains low and it decreased significantly in the period from 2002 to 2005. 45 From this brief analysis it is evident that weight reductions of 5 --10% will not meet the expectations of patients or physicians. We estimate that any new entrant to the obesity market will need to produce a 10 --15% reduction in body weight to be considered clinically effective by patients and physicians. The natural progression of active weight loss into weight loss maintenance will remain a significant barrier to the retention of patients on antiobesity drug therapy, especially in the situation where the patient has to contribute wholly or partly to the cost of such drugs. These unmet needs will have to be addressed by any new drug entering the antiobesity market for it to have a reasonable chance of being a commercial success. These points will be considered when evaluating late-stage drug candidates that are reviewed in this manuscript.
NEW CNS APPROACHES
Research in the obesity field has greatly improved our understanding of the complex system of central and peripheral networks that regulate both food intake and energy expenditure and has revealed a wealth of new central and peripheral targets for the discovery and development of novel antiobesity drugs.
Monoaminergic targets 5-HT 2C receptor agonists. In animal experiments, the hypophagic effect of fenfluramine is mediated by indirect activation of 5-HT 2C (5-hydroxytryptamine (serotonin) receptor 2C) receptors, 37, 46 whereas unwanted actions derive from activation of 5-HT 2A and 5-HT 2B receptors. Rothman and co-workers 47 --49 demonstrated that activation of cardiac valve tissue 5-HT 2B receptors by dfenfluramine induces cellular proliferation, possibly responsible for development of inelasticity and loss of function. The 5-HT 2A receptor may mediate the hallucinogenic actions of serotonergic agonists, for example, DOI (2,5-dimethoxy-4-iodoamphetamine) and 5-methoxy-N,N-dimethyltryptamine. 50, 51 Fenfluramine is hallucinogenic in human volunteers when given at high doses. In preclinical experiments, the 5-HT 2C agonists, m-chlorophenylpiperazine (mCPP) and Ro 60-0175, reduced food intake of normal rats when given either acutely or chronically and also substantially reduced body weight gain. 53, 54 VER-8775 is a highaffinity (K i ¼ 6 nM), high-efficacy (B75% intrinsic efficacy) 5-HT 2C agonist with B19-fold and B70-fold selectivity versus 5-HT 2A and 5-HT 2B receptors, respectively. 55 In obese mice maintained on a high-fat diet, VER-8775 (20 and 30 mg kg À 1 p.o., b.i.d) dosedependently and profoundly decreased body weight over 28 days. 56 The reduction of body weight and the maintenance of weight loss were due to sustained decrease in food intake. These data provided unequivocal evidence to support the hypothesis that 5-HT 2C agonists were potentially effective antiobesity drugs. However, none of the 5-HT 2C agonists delivered a greater degree of weight loss than d-fenfluramine in comparator experiments. 46 If these preclinical findings translated into clinical outcomes, the prediction would be that 5-HT 2C agonists would be no more effective in treating obesity than d-fenfluramine. Although VR 1065 progressed into phase 1 clinical development, its pharmacokinetic profile was not acceptable. There is no public information to indicate whether its successor, VER-8775, was evaluated in humans.
Lorcaserin (Arena/Eisai (Tokyo, Japan)) has undergone a full programme of preclinical and clinical evaluation. It is a highaffinity 5-HT 2C receptor full agonist (K i : h5-HT 2C ¼ 15 ZM; r5-HT 2C ¼ 29 ZM) devoid of affinity for a wide panel of other G-protein-coupled receptors and ion channels. With respect to 5-HT 2A and 5-HT 2B receptor subtypes, locaserin has selectivity ratios of B15-and 100-fold, respectively. 57 The clinical benefits of lorcaserin have been determined in two, large, randomised, double-blind, placebo-controlled, multicentre phase 3 clinical trials in obese subjects (Behavioural modification and Lorcaserin for Overweight and Obesity Management (BLOOM)) and Behavioural modification and LOrcaserin Second Study for Obesity Management (BLOSSOM)) and a 1-year trial in obese and overweight adults with type 2 diabetes (BLOOM-DM). In the 2-year BLOOM trial, patients were randomised to placebo or lorcaserin 10 mg b.i.d. for 12 months with completers being randomised 1:1 to remain on lorcaserin treatment or switched to placebo. In the 1-year BLOSSOM trial, 2 doses of lorcaserin, that is, 10 mg q.d. and 58 Guy-Grand et al., 59 Lorcaserin NDA 87 and Hanotin et al.
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The analysis of the weight-reducing efficacy of lorcaserin in the BLOOM trial 58 is shown in Figure 1 . The placebo-subtracted efficacy of lorcaserin at 1 year was 3.6 kg and this reduction is strikingly similar to the 3.5 kg weight loss produced by d-fenfluramine (Figure 1) . 59 In the BLOSSOM trial, 60 the placebo-subtracted weight reduction recorded at 1 year on treatment with lorcaserin 10 mg b.i.d. was lower at 2.9 kg (Figure 1 ). In addition to producing very moderate weight loss after 12 months in both phase 3 studies, the year 2 results from the BLOOM trial revealed the worrying emergence of tolerance to lorcaserin in the drug-responder group. The primary end point for year 2 was to determine, in patients who had lost at least 5% of baseline body weight at week 52, the proportion who maintained this degree of weight loss at the end of the second year of treatment. Subjects meeting the 5% weight reduction criteria on lorcaserin treatment were randomised either to continue active treatment (lorcaserin 10 mg b.i.d.) or were switched to placebo. As shown in Figure 1 , although the rate of weight regain in subjects continuing lorcaserin therapy was slower than observed in subjects who had been switched to placebo, the slope of the upward trajectory was much steeper than that observed in the placebo/placebo group of subjects. Consistent with the emergence of pharmacological tolerance, the difference between the percentage of patients achieving X5% weight loss on lorcaserin versus placebo decreased from 27.2% at week 52 to 17.6% at week 104.
Although results from the BLOOM-DM trial in obese subjects with type 2 diabetes have not yet been published in a peerreviewed article, some of the key data from the study have appeared in a press release from Arena. 61 Because of the anabolic effects of insulin and repeated efforts to control their type 2 diabetes through dieting, it is notoriously difficult to obtain good weight reduction with antiobesity drugs in this patient population. In the case of lorcaserin, the 3.1 kg placebo-subtracted weight loss reported in obese diabetics was surprisingly little different from the reductions recorded in trials of lorcaserin in nondiabetic obese subjects. 55, 57 This observation was confirmed by the corresponding responder analyses that revealed that X5% weight loss was achieved by 21.4% in obesity with type 2 diabetes 61 compared with 22.2% and 27.2% in the BLOOM 58 and BLOSSUM 60 trials, respectively.
The benefits of lorcaserin therapy on a range of cardiovascular risk factors are summarised in Table 2 . All of the metabolic effects of lorcaserin were consistent with a reduction in cardiovascular risk. There was no evidence to suggest that it improves cardiometabolic function by a mechanism that is independent of weight loss. Therefore, although the effects of lorcaserin on a range of cardiovascular risk factors are highly statistically significant and act cooperatively to reduce cardiovascular risk, the magnitude of the changes is small and of questionable clinical significance.
The abuse potential of lorcaserin was evaluated in drugexperienced human volunteers. 62 Lorcaserin was tested at 20 --60 mg p.o. and its effects were compared with a low dose of an NMDA (N-methyl-D-aspartate) antagonist (ketamine 100 mg p.o.), or the sedative euphoriant benzodiazepine, zolpidem 15 mg or 30 mg p.o., but no comparison was made against either a serotonergic hallucinogen or MDMA (3,4-Methylenedioxymethamphetamine). There was no mention of any hallucinogenic effect of lorcaserin, but the two highest doses evoked subjective effects of 'floating', 'spaced out' and 'euphoric mood'. 63 Overall, the experience of lorcaserin was neither liked nor valued by experienced drug users. According to Arena, the FDA has indicated that lorcaserin will be classified as a Schedule 4 Controlled Drug in the United States. 61 Common adverse events associated with lorcaserin were consistent with its serotonergic agonist mechanism of action, that is, increased incidences of blurred vision, dizziness, somnolence, headache, gastrointestinal disturbance and nausea. The possible induction of cardiac valvulopathy was the greatest safety concern in the development of lorcaserin, but extensive echocardiographic testing throughout its development revealed no cardiotoxic action of the compound.
The other major safety concern highlighted by the FDA in its non-approvable letter was an increased incidence of mammary adenocarcinomas in female rats and brain astrocytomas in male rats. In January 2012, Arena announced that it had prepared and submitted its responses to the FDA on safety concerns relating to lorcaserin and had resubmitted its NDA with a view to having a decision on the approvability of the compound in June 2012. 32 At this time, lorcaserin has not been submitted to EMA for European registration. On the basis of the current clinical data, the efficacy of lorcaserin would not appear to meet the European regulatory requirement, that is, 10% overall weight reduction from baseline. Also, EMA has only recently moved from requiring 2-year efficacy data. In this regard, the emergence of tolerance to the weight-reducing actions of lorcaserin in the BLOOM trial provides additional evidence to indicate that the drug is unlikely to receive regulatory approval from EMA.
As the weight loss effect of lorcaserin is probably less than that of sibutramine or rimonabant, and probably not very different from that of the Schedule 4 Controlled Drug anorectic, phentermine, it is difficult to foresee its reimbursement by most medical insurance providers, or its long-term clinical use funded by the patients themselves.
Controlled-release phentermine. Phentermine is one of a wide range of b-phenylethylamine analogues that were synthesised in the 1950s in the search for new sympathomimetic anorectics with the efficacy of d-amphetamine and methamphetamine, but a reduced liability for recreational abuse. Phentermine resides in a much lower controlled drug schedule than d-amphetamine and methamphetamine. Although phentermine was removed from the market in Europe in 2001 for concerns about its safety and a lack of evidence of sustained clinical benefit in the management of obesity, it is the most widely prescribed weight loss drug in the United States. Clinical results have recently been published for a new diffuse-controlled release formulation of phentermine (DCRphentermine). In this small (74 subjects), 12-week, randomised, double-blind, placebo-controlled trial, DCR-phentermine produced a placebo-subtracted weight loss of 6.4 kg with 75% and 59% of subjects achieving X5% and X10% reductions from baseline body weight, respectively. 64 The decreased obesity was accompanied by reductions in waist circumference, low-density lipoprotein cholesterol and total cholesterol. The adverse effects were typical of the sympathomimetics, for example, dry mouth and insomnia, but importantly there were no drug-related increases in systolic blood pressure (SBP) or diastolic blood pressure (DBP). 64 Although these results need confirmation and extension in larger and longer pivotal trials, DCR-phentermine would appear to offer greater efficacy than some of the newer drug candidates that are awaiting approval. The issue of drug dependence is an important consideration for drugs of this type. It has recently been reported that abrupt cessation of phentermine in obese subjects on long-term therapy with this psychostimulant did not evoke withdrawal or drug craving. 65 Fixed-dose drug combinations The move by several biotech companies to develop fixed-dose combinations containing approved CNS drugs to treat obesity has a number of drivers. First, it is evident that weight loss can be achieved using currently available antiobesity drugs and they deliver medical benefits to the patient in terms of improved glycaemic control, reduced plasma concentrations of dangerous lipids and reductions in blood pressure. 20, 66, 67 However, the degree of weight loss falls short of the expectations of physicians Late-stage CNS drug candidates for obesity DJ Heal et al 68 who combined moderate doses of fenfluramine and phentermine, and delivered substantial weight reductions in patients. This contrasted with the relatively moderate effect of d-fenfluramine or phentermine on body weight when given individually. 36, 59, 69 The hypothesis was that fenfluramine as a 5-HT-releasing agent and phentermine as a noradrenaline-releasing agent had different, but synergistic, pharmacological mechanisms that would increase weight loss efficacy while also improving safety by reducing the therapeutic dose of each drug. In reality, both drugs had relatively nonselective actions, 70 --72 an aspect not well understood at the time and when off-label prescribing of phentermine and fenfluramine gained popularity in the United States, the outcome was a substantial incidence of cardiac valve damage. 28, 73 A major consequence was to ensure that drug combination antiobesity therapies would have to be thoroughly investigated to evaluate their efficacy and safety.
Contrave (bupropion þ naltrexone).
Orexigen is developing a fixeddose combination of bupropion þ naltrexone (Contrave) . Bupropion is a weak, selective dopamine reuptake inhibitor 74 used as a treatment for depression (Welbutrin) and to aid smoking cessation (Zyban). Bupropion has undergone some clinical testing as an aid to weight management, particularly in subjects attempting to quit smoking, and, overall, the data showed that it was only weakly effective. 75, 76 Naltrexone (Vivitrol) is a well-known opioid receptor antagonist that is used clinically to treat opiate and alcoholdependence syndromes.
The efficacy and safety of Contrave have been determined in four pivotal, 56-week, multicentre, randomised, double-blind placebo controlled studies, that is, NB-301 (n ¼ 1742 subjects), NB-302 (n ¼ 793 subjects), NB-303 (n ¼ 1496 subjects) and NB-304 (n ¼ 505 subjects). NB-301, NB-302 and NB-303 were trials in subjects in uncomplicated obesity, or overweight/obesity with controlled hypertension and/or dyslipidaemia. In NB-302, the efficacy of Contrave was determined when employed as an adjunct to intensive diet, exercise and lifestyle modification. NB-304 was a trial in overweight and obese subjects with type 2 diabetes with/without controlled hypertension and/or dyslipidaemia. In NB-301, NB-303 and NB-302, 85 --90% of the subjects enroled were female and 70 --84% Caucasian. 77 Contrave was tested at two doses, that is, naltrexone 16 mg þ bupropion 360 mg and naltrexone 32 mg þ bupropion 360 mg, in NB-301, but only at the higher dose in NB-302 and NB-303. At week 56, the placebosubtracted weight reductions produced by the higher dose of Contrave were 4.8 and 5.2 kg in NB-301 and NB-303, respectively. In NB-302, which included intensive dietary and behavioural support, Contrave produced 4.2 kg weight loss (Table 2 ). In obese subjects with type 2 diabetes who are notoriously resistant to the actions of antiobesity drugs, Contrave produced a placebosubtracted weight loss of 3.4 kg. A categorical analysis of efficacy revealed that after correction for placebo, the proportion of subjects treated with the higher dose of Contrave who achieved X5% and X10% reductions of body weight from baseline were 24 --37% and 18 --22%, respectively (Table 2) . 77 In terms of its ability to reduce body weight, the efficacy of Contrave approximates to sibutramine or rimonabant. In comparison with other fixed-dose antiobesity drug combinations and monotherapies, which are in the pre-registration phase, Contrave ranks below Qnexa in terms of weight loss efficacy, but above lorcaserin ( Table 2 ). The clinical data showed no evidence of any weight-loss-independent benefits of Contrave with improvements in various obesity-related, cardiovascular risk factors being commensurate with reductions of body weight. Decreases in waist circumference paralleled reductions in body weight (Table 2) . Contrave also produced clinically beneficial decreases in plasma triglycerides and increases in high-density lipoprotein cholesterol, but had relatively little effect on plasma low-density lipoprotein cholesterol (Table 2 ). In non-diabetic subjects, Contrave reduced both fasting plasma insulin and glucose concentrations, leading to an overall improvement in insulin sensitivity (Table 2 ). In obese subjects with type 2 diabetes, an average, placebo-subtracted reduction of almost 0.5% in plasma HbA 1c was observed. 77 Blood pressure did not decrease in line with weight loss on Contrave treatment. When results for all subjects receiving high-dose Contrave (naltrexone 32 mg/bupropion 360 mg) were averaged, SBP was unchanged from baseline and DBP was decreased by 0.7 mm Hg, compared with average decreases of 1.5 and 1.3 mm Hg in the placebo-treated subjects. Hence after placebo subtraction, Contrave produced small increases in both SBP and DBP (Table 2) . In a more detailed analysis, 77 subjects needed to lose between 5% and 10% of their body weight to achieve decreases from baseline of 0.5 and 0.6 mm Hg in SBP and DBP, respectively, whereas those achieving X10% weight loss reduced their SBP and DBP by B2 mm Hg. In contrast, the small number of subjects who managed X10% weight loss on placebo experienced decreases of 6.1 mm Hg in SBP and 4.0 mm Hg in DBP. In addition to having a propensity to increase blood pressure, Contrave slightly increased the incidence of hypertension and palpitations. The most frequent side effects of this drug were gastrointestinal, 77 likely to be linked to the opioid antagonist actions of naltrexone. Other adverse events include headache, dizziness, insomnia and dry mouth, 77 probably derived from bupropion's pharmacology as a catecholamine reuptake inhibitor. The use of Contrave was not linked with an increased incidence of psychiatric adverse events or suicidal ideation.
Although the independent Advisory Committee of FDA voted to recommend approval of Contrave, the FDA declined the application in January 2011 because of the safety risk to patients from increases in blood pressure. The agency said that it needs to see acceptable safety data for Contrave from a long-term cardiovascular outcome trial before it would grant it approval as an antiobesity treatment. In the light of the recent withdrawal of sibutramine, which had similar effects on blood pressure, because of an increased incidence of nonfatal cardiovascular events, the decision by FDA looks reasonable and fair. Orexigen recently announced that it has reached a tentative agreement with the FDA over the design of the cardiovascular outcome trial and will conduct it with a view to resubmitting the NDA for Contrave in 2013 or 2014.
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Based on current data, Contrave would not satisfy the criterion of EMA for a clinically effective antiobesity drug. Although the degree of weight loss produced by Contrave may not preclude its approval of in Europe, its action to increase in SBP and DBP will be carefully considered in the benefit/risk assessment of EMA. In the light of the request by the FDA for additional clinical data on cardiovascular safety, and having only recently suspended sibutramine on the basis of the SCOUT results, EMA could decide to delay its decision on approving Contrave until new clinical data are available. Moreover, even if Contrave does obtain approval from EMA, the agency is almost certain to insist on a commitment from Orixigen to perform a large phase 4 cardiovascular outcome study.
It now clear that there will be a significant delay before Contrave enters the market in the United States. As approval will be based on the demonstration that Contrave does not increase cardiovascular risk, it will remove a major obstacle preventing physicians from prescribing this drug to their obese and overweight patients. However, unless Contrave is shown to significantly reduce adverse cardiovascular events, cf the statins, the drug is unlikely to be reimbursed by health-care insurers, leaving the cost burden of the drug on patients. As the majority of patients are unlikely to achieve the high degree of weight loss that they are seeking, it is questionable how willing they will be to pay for Contrave. As previously seen with sibutramine and orlistat, there may a very high initial uptake of Contrave treatment that is followed by a quite rapid decline.
Qnexa (phentermine þ topirimate). A fixed-dose combination containing phentermine and topirimate (Qnexa) is being developed by Vivus. Phentermine, the nonselective releaser of noradrenaline, dopamine and 5-HT, 71, 72, 79 has been used as a short-term appetite suppressant since the 1960s. Topirimate is a marketed anticonvulsant drug and following anecdotal reports of weight loss occurring in epileptic patients, it was evaluated as a potential antiobesity drug in clinical trials. Topirimate produced a very substantial weight reduction in obese subjects, 80 --82 but its development was halted by J&J (New Brunswick, NJ, USA) because its side-effect profile was not acceptable. The pharmacological mechanism underpinning the beneficial effect of topirimate on body weight has not been elucidated, but may derive in part from potent inhibition of mitochondrial carbonic anhydrase V. 83 Qnexa has been evaluated in clinical trials at three different dosages, that is, phentermine (mg)/topirimate (mg): 3.75/23 (low dose), 7.5/46 (mid dose) and 15/92 (full dose). The scientific rationale for this approach was that the pharmacological mechanisms of these two centrally acting drugs would be either additive or synergistic, and by combining them at relatively low doses, greater weight loss could be achieved with reduced side effects.
Where these drugs were administered both alone and in combination to groups of obese patients in a phase 2 trial, the number of patients on the topirimate þ phentermine combination achieving X10% placebo-subtracted weight loss was 42%, which is considerably greater than the proportion of patients achieving this end point on orlistat, sibutramine or rimonabant. The effects of combined phentermine and topirimate were approximately additive. Consistent with a reduction in obesity, patients treated with the combination therapy showed reductions in blood pressure and unhealthy plasma lipids. 84 Although a substantial number of clinical trials with Qnexa have been performed, in this review we will concentrate on results from the two, large, 1-year phase 3 pivotal trials: OB-302 and OB-303. OB-302 was a trial performed in severe obesity (BMI X40 kg m --2 ) in 1267 subjects without other comorbid metabolic disorders. Most subjects in OB-302 were female (82.9%) and Caucasian (80%) and the mean age of subjects was 42.6 years. At baseline, the mean weight of the subjects was 116.1 kg with a mean BMI of 42.1 kg m --2 . The low and full dose of Qnexa was evaluated in this group of subjects. At week 56, the placebo-subtracted weight loss was 4.1 kg (3.5%) and 10.9 kg (9.4%) for the low and full doses of Qnexa, respectively (Table 2) . OB-303 was a randomised, doubleblind, placebo-controlled, multicentre trial in overweight or obese subjects who also had two or more weight-related comorbid disorders, that is, hypertension or treatment with X2 antihypertensive medications, elevated plasma triglycerides or a requirement for X2 lipid-lowering medications, glucose intolerance, a diagnosis of type 2 diabetes managed by lifestyle interventions, or metformin monotherapy and visceral adiposity (X102 cm for men and X88 cm for women). Again, most subjects were female (69.7%) and Caucasian (86%). At baseline, the mean weight was 103.1 kg with a mean BMI of 36.6 kg m --2 . In this population, the mid and high doses of Qnexa were evaluated for efficacy and safety. At week 56, the placebo-subtracted weight loss was 6.8 kg (6.6%) and 8.9 kg (8.6%) on treatment with the mid and full doses of Qnexa, respectively 85 (Table 2 ). In both OB-302 and OB-303, subjects receiving the full dose of Qnexa achieved X10% reduction in body weight from baseline, with no evidence of any loss of pharmacological efficacy for Qnexa throughout the 1-year treatment period. Evidence for a lack of pharmacological tolerance to Qnexa was provided by data from the OB-305 extension trial. In this double-blind, placebo-controlled study, a subset of subjects (n ¼ 675) who had completed the 56-week OB-303 study were maintained on their existing treatments for an additional 52 weeks. The percentages of subjects (placebo subtracted) who had achieved X10% weight loss on the mid dose of Qnexa were 39.4% at week 56 and 38% at week 108. The corresponding figures for the high dose of Qnexa were 54.6% at week 56 and 42% at week 108. 85 Although there is no evidence to suggest that its benefits on cardiovascular risk exceed those due to weight loss, improvements in plasma lipid profiles, glycaemic control and blood pressure are substantially greater than those produced by lorcaserin because of the greater weight loss efficacy of Qnexa (Table 2 ). When these results were analysed according to the metabolic disease subgroup, the improvements in cardiovascular risk factors were invariably greater than those reported in the overall group. 85 Adverse events associated with Qnexa treatment were generally consistent with those reported for phentermine (i.e., dry mouth, constipation, insomnia, and palpitations) and for topirimate (i.e., dizziness, paraesthesia and disturbances in attention), together with headache, dysgeusia (distortion of sense of taste), alopecia and hypokalaemia. 85 The Neuroendocrine Pharmaceutical Advisory Committee focused heavily on safety concerns related to a very small increase in heart rate associated with Qnexa, topirimate's known potential to produce birth defects and an increased incidence of depression and anxiety as treatmentemergent adverse events.
Many antiepileptic drugs including topiramate are known to cause birth defects in humans, and as the prescribing of antiobesity drugs is predominantly to females in the 35 --55 year age group, the safety concerns of FDA were well founded. However, the issue is complex because the doses of topiramate used in Qnexa are much lower than those required for the management of epilepsy, and there were significant differences across the epidemiological databases that have estimated the teratological risks of antiepileptic drugs, and epilepsy itself is associated with an increased number of birth defects. Vivus is addressing these questions by conducting a retrospective review of the incidence of birth defects in woman taking topiramate during pregnancy. In the meantime, the company submitted a revised NDA in October 2011 for the use of Qnexa in the treatment of obesity in men and women without child-bearing potential 30 with a view to extending the labelling to include all women if the results from its retrospective analysis are supportive. On 22 February 2012 FDA's Advisory Committee stated that the health risks of obesity outweighed those of potential birth defects and recommended that Qnexa be approved to treat adult obesity in males and females.
Vivus is pursuing the registration of Qnexa for the treatment of obesity in Europe on the basis of the data presented in the US NDA. The full dose of Qnexa would satisfy the EMA criterion for clinically relevant weight loss, that is, X10% of baseline weight. Furthermore, the weight loss effect of the mid dose of Qnexa obtained in OB-303 comes very close to meeting this criterion as well. The European experience with respect to obesity pharmacotherapy is very different from that in the United States. Phentermine was used only sparingly in European countries and its marketing authorisation was withdrawn in 2000 because of safety concerns related to all of the older sympathomimetic drugs. Although it will probably not impede the approval of Qnexa in Europe, Vivus will not be able to argue that Qnexa's active moieties are widely prescribed, safe and effective medications.
Also because phentermine is a well-known sympathomimetic agent and concerns have already been raised by the Advisory Committee of FDA about increases in heart rate, it is likely that EMA will request a commitment to perform a large phase 4 cardiovascular outcome trial as part of the approval. It is to be hoped that in this instance, the mandated trial will be performed in an appropriate patient population as defined by Qnexa's European SPC. Phentermine has a neurochemical and behavioural profile closely resembling that of the psychostimulant, d-amphetamine. Because of its potential for abuse and dependence, phentermine is a Schedule 4 drug in the United States, but Schedule 3 in the United Kingdom. Any combination medication including phentermine will be classified as a Controlled Drug.
In summary, Qnexa is the most efficacious of the three centrally acting antiobesity drugs currently seeking market authorisation in the United States and it is almost certainly superior to orlistat, rimonabant and sibutramine. It is also the only antiobesity drug candidate that unequivocally satisfies the European regulatory requirements for approval in this indication. Birth defects are an important safety issue that remains to be resolved. In the meantime, if the FDA approves Qnexa for use in men and postmenopausal women, a major challenge will be to prevent the use of this antiobesity medication by the at-risk female population. If Qnexa passes these safety hurdles, the magnitude of its weight loss effect may be sufficient to satisfy a significant proportion of physicians and their patients.
Empatic (bupropion þ zonisamide). Bupropionþ zonisamide (Empatic) is being developed by Orexigen and is currently in phase 3. The pharmacology of bupropion has been described above. Zonisamide (Zonegran) is an anticonvulsant drug. Orexigen recently reported results for different fixed-dose combinations of Empatic from a placebo-controlled double-blind phase 2 trial in obese subjects. At 48 weeks, patients experienced placebo-subtracted, substantial weight losses of between 9 and 12.9%, depending on the doses of bupropion þ zonisamide used. 86 A more complete understanding of the benefit/risk profile of Empatic will emerge when results from phase 3 become available. However, as Orexigen recently placed a hold on the clinical development of all its obesity therapies, it is now uncertain whether these data will ever be available.
Overall, when considering these two fixed-dose combination products that are being developed by Orexigen, the bupropion þ zonisamide combination appears to show more promise in delivering weight loss than bupropion þ naltrexone. One question mark over Empatic is whether the anticonvulant, zonisamide, has any potential to cause birth defects.
FUTURE DIRECTIONS
Drug development in obesity has suffered a considerable setback in the wake of the introduction and rapid suspension of rimonabant in Europe and its failure to gain approval in the United States. This episode has placed a greater emphasis on drug safety in the obesity indication, which has been interpreted in some quarters of the pharmaceutical industry to indicate that the hurdles to achieve marketing approval for CNS drugs have increased substantially. A careful evaluation of the statements made by EMEA and FDA indicate this may not be the case. 35 Preclinical research has revealed a greater understanding of the complex nature of the hypothalamic regulation of food intake and, in turn, this has generated a wide range of new molecular targets for the development of drug candidates to treat obesity. The clinical results obtained with this next generation of therapies show that some approaches, for example, fixed-dose drug combinations, have already demonstrated an ability to deliver levels of efficacy that are not achievable with the current antiobesity drug therapies. However, in the clinical situation, efficacy will need to be carefully balanced against tolerability and safety in order to achieve the optimum benefit/risk outcome. Some assistance for the management of obese subjects with type 2 diabetes has been given by the introduction of the weightreducing incretin drugs, for example, the injectable GLP analogue, exenatide, and the GLP-1 agonists, for example, sitagliptin, vildapgliptin and liraglutide. However, to the best of our knowledge, liraglutide is the only one of these compounds that is currently being developed for the indication of obesity.
In summary, with the global epidemic of obesity showing no signs of abating, it is hoped that some of the drug candidates, which are currently in preclinical and clinical development, will go on to deliver the improvements in efficacy with acceptable safety profiles that are so urgently required to tackle the obesity healthcare problem.
